New lung cancer cocktail aims to outperform current standard
NCT ID NCT07170995
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding a new drug (SHR-8068) to a standard immunotherapy (adebrelimab) and chemotherapy works better than the current standard (tislelizumab plus chemo) for people with advanced non-small cell lung cancer. About 460 participants will be randomly assigned to one of the two treatments. The study measures how long people live without their cancer getting worse and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-8068, adebrelimab, and platinum-based chemotherapy
What this could lead to
If this works, it could offer a new first-line treatment option for advanced lung cancer that may be more effective than current standard therapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. The new combination may not improve survival or could cause more side effects than the standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, 250117, China
Contact